Tyra Biosciences, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $301.7M | $302.2M |
| FY2022 | — | $257.8M | $251.2M |
| FY2023 | — | $204.3M | $58.0M |
| FY2024 | — | $343.2M | $92.0M |
| FY2025 | — | $259.2M | $77.4M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $301.7M | $302.2M |
| FY2022 | — | $257.8M | $251.2M |
| FY2023 | — | $204.3M | $58.0M |
| FY2024 | — | $343.2M | $92.0M |
| FY2025 | — | $259.2M | $77.4M |